ProfileGDS5678 / 1455417_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 84% 86% 84% 85% 90% 88% 87% 86% 85% 86% 85% 86% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.50586
GSM967853U87-EV human glioblastoma xenograft - Control 26.3394384
GSM967854U87-EV human glioblastoma xenograft - Control 36.4869186
GSM967855U87-EV human glioblastoma xenograft - Control 46.4423984
GSM967856U87-EV human glioblastoma xenograft - Control 56.4529685
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8877490
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6803388
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5675487
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5066886
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3777285
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4842286
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3775685
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5869986
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.4921886